- Healthcare Professionals
- OncoLink Scientific Meetings Coverage
- OncoLink at ASCO 2001
- OncoLink at ASCO 2001: Monday, May 14
Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor Multicenter phase II study
Li Liu, MD
University of Pennsylvania Cancer
Last Modified: May 14, 2001
Presenter: C. Louvet
Affiliation: Hospital St-Antoine, Paris France
Gemcitabine has been shown to be an active agent in the treatment of pancreatic cancer. Some preclinical data showed that the combination of gemcitabine with oxaliplatin (GEMOX) exerts potent antiproliferative effects in human cancer cell lines, including colon cancer.
Materials and Methods:
- A total of 64 patients with advanced pancreatic carcinoma (APC) were included in this phase II study.
- Patients received the GEMOX every 2 weeks for 6 cycles followed by chemoradiation.
- Oxaliplatin dose was 100 mg/m2 with 2 hour indusion and gemcitabine was given 1000 mg/m2 every 2 weeks.
- Chemoradiaiton with 5-FU was used in patients with stage II/III diseases.
19 patients achieved partial remission, 28 stable disease, and 16 progression of disease
- Median progression-free survival was 21 weeks.
- 6-month survival was 71%.
- Treatment was well tolerated.
- Neutropenia, thrombodytopenia, and nausea and vomiting were the common toxicities.
- GEMOX appeared to be active and well tolerated in patients with APC.
- The remarkable low toxicity is of major value in this palliative situation.
- This regimen will be tested in a phase III randomized study comparing GEMOX versus gemcitabine alone.
OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen